Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 6, 2006, Pages 785-793

  Takara, Kohji ^a   Obata, Yukihisa ^a   Yoshikawa, Eri ^a   Kitada, Noriaki ^a   Sakaeda, Toshiyuki ^b   Ohnishi, Noriaki ^a   Yokoyama, Teruyoshi ^a  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b KOBE UNIVERSITY   (Japan)

Author keywords

Cisplatin; HeLa cell; MDR1 P glycoprotein; Multidrug resistance; Paclitaxel

Indexed keywords

ACLARUBICIN; BETA TUBULIN; BLEOMYCIN; BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; GLUTAMATE CYSTEINE LIGASE; GLYCOPROTEIN P; MESSENGER RNA; MITOMYCIN C; MULTIDRUG RESISTANCE PROTEIN 1; NEDAPLATIN; PACLITAXEL; PIRARUBICIN; PLATINUM DERIVATIVE; TAMOXIFEN; TAXANE DERIVATIVE; VINBLASTINE; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CROSS RESISTANCE; HELA CELL; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BCL-2-ASSOCIATED X PROTEIN; CELL PROLIFERATION; CISPLATIN; CYCLOSPORINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GAMMA-GLUTAMYLTRANSFERASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMATE-CYSTEINE LIGASE; HELA CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, STEROID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUBULIN;

EID: 33748446622     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0226-5     Document Type: Article

References (38)

1. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265-7279
2. Wang G, Reed E, Li QQ (2004) Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncol Rep 12(5):955-965
3. Torigoe T, Izumi H, Ishiguchi H, Yoshida Y, Tanabe M, Yoshida T, Igarashi T, Niina I, Wakasugi T, Imaizumi T, Momii Y, Kuwano M, Kohno K (2005) Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 5(1):15-27
4. Takara K, Sakaeda T, Okumura K (2006) An update on overcoming MDR1-mediated multidrug resistance in cancer. Curr Pharm Des 12(3):273-286
5. Longley DB, Johnston PG (2005) Molecular mechanisms of drug resistance. J Pathol 205(2):275-292
6. Takara K, Sakaeda T, Okumura K (2004) Carvedilol: a new candidate for reversal of MDR1/P-glycoprotein-mediated multidrug resistance. Anticancer Drugs 15(4):303-309
7. Takara K, Sakaeda T, Yagami T, Kobayashi H, Ohmoto N, Horinouchi M, Nishiguchi K, Okumura K (2002) Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull 25(6):771-778
8. Abbott BL (2003) ABCG2 (BCRP) expression in normal and malignant hematopoietic cells. Hematol Oncol 21(3):115-130
9. Hoffmann U, Kroemer HK (2004) The ABC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance. Drug Metab Rev 36(3-4):669-701
10. Leonard GD, Fojo T, Bates SE (2003) The role of ABC transporters in clinical practice. Oncologist 8(5):411-424
11. Takara K, Horibe S, Obata Y, Yoshikawa E, Ohnishi N, Yokoyama T (2005) Effects of 19 herbal extracts on the sensitivity to paclitaxel or 5-fluorouracil in HeLa cells. Biol Pharm Bull 28(1):138-142
12. 1 cells. Biol Pharm Bull 26(2):205-209
13. Takara K, Tsujimoto M, Ohnishi N, Yokoyama T (2002) Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commun 292(1):190-194
14. Takara K, Tsujimoto M, Ohnishi N, Yokoyama T (2003) Effects of continuous exposure to digoxin on MDR1 function and expression in Caco-2 cells. J Pharm Pharmacol 55(5):675-681
15. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265-275
16. Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T (2003) Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneously down-regulates steroid xenobiotic receptor mRNA. Biochem Biophys Res Commun 306(1):116-120
17. Carles G, Braguer D, Dumontet C, Bourgarel V, Goncalves A, Sarrazin M, Rognoni JB, Briand C (1999) Differentiation of human colon cancer cells changes the expression of beta-tubulin isotypes and MAPs. Br J Cancer 80(8):1162-1168
18. Daubeuf S, Accaoui MJ, Pettersen I, Huseby NE, Visvikis A, Galteau MM (2001) Differential regulation of γ-glutamyltransferase mRNAs in four human tumour cell lines. Biochim Biophys Acta 1568(1):67-73
19. Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukumoto M, Takebayashi Y (2001) Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 92(4):452-458
20. Kavallaris M, Kuo DY, Burkhart CA, Regl DL, Norris MD, Haber M, Horwitz SB (1997) Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100(5):1282-1293
21. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F, Borst P (1997) Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57(16):3537-3547
22. Liu B, Staren ED, Iwamura T, Appert HE, Howard JM (2001) Mechanisms of taxotere-related drug resistance in pancreatic carcinoma. J Surg Res 99(2):179-186
23. Myhrstad MC, Carlsen H, Nordstrom O, Blomhoff R, Moskaug JO (2002) Flavonoids increase the intracellular glutathione level by transactivation of the γ-glutamylcysteine synthetase catalytical subunit promoter. Free Radic Biol Med 32(5):386-393
24. Oudard S, Levalois C, Andrieu JM, Bougaran J, Validire P, Thiounn N, Poupon MF, Fourme E, Chevillard S (2002) Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res 22(1A):121-128
25. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254
26. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227(5259):680-685
27. Synold TW, Dussault I, Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7(5):584-590
28. Li Q, Sai Y, Kato Y, Tamai I, Tsuji A (2003) Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines. Pharm Res 20(8):1119-1124
29. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89(7):3070-3074
30. Kotoh S, Naito S, Yokomizo A, Kohno K, Kuwano M, Kumazawa J (1997) Enhanced expression of γ-glutamylcysteine synthetase and glutathione S-transferase genes in cisplatin-resistant bladder cancer cells with multidrug resistance phenotype. J Urol 157(3):1054-1058
31. Kurokawa H, Ishida T, Nishio K, Arioka H, Sata M, Fukumoto H, Miura M, Saijo N (1995) γ-glutamylcysteine synthetase gene overexpression results in increased activity of the ATP-dependent glutathione S-conjugate export pump and cisplatin resistance. Biochem Biophys Res Commun 216(1):258-264
32. Tipnis SR, Blake DG, Shepherd AG, McLellan LI (1999) Overexpression of the regulatory subunit of γ-glutamylcysteine synthetase in HeLa cells increases γ-glutamylcysteine synthetase activity and confers drug resistance. Biochem J 337(3):559-566
33. El-akawi Z, Abu-hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ, Pendyala L (1996) Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 105(1):5-14
34. Daubeuf S, Balin D, Leroy P, Visvikis A (2003) Different mechanisms for gamma-glutamyltransferase-dependent resistance to carboplatin and cisplatin. Biochem Pharmacol 66(4):595-604
35. Ranganathan S, Benetatos CA, Colarusso PJ, Dexter DW, Hudes GR (1998) Altered β-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 77(4):562-566
36. Johnstone RW, Cretney E, Smyth MJ (1999) P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 93(3):1075-1085
37. Sakaeda T, Nakamura T, Hirai M, Kimura T, Wada A, Yagami T, Kobayashi H, Nagata S, Okamura N, Yoshikawa T, Shirakawa T, Gotoh A, Matsuo M, Okumura K (2002) MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. Pharm Res 19(9):1323-1329
38. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW (1998) The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci USA 95(12):7024-7029